Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172785218> ?p ?o ?g. }
- W3172785218 abstract "Abstract The coronavirus disease 2019 (COVID‐19) pandemic has triggered a global health emergency and brought disaster to humans. Tremendous efforts have been made to control the pandemic, among which neutralizing antibodies (NAbs) are of specific interest to researchers. Neutralizing antibodies are generated within weeks after infection or immunization and can protect cells from virus intrusion and confer protective immunity to cells. Thus, production of NAbs is considered as a main goal for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines and NAbs may be used for patient treatment in the form of monoclonal antibodies. Neutralization assays are capable of quantitatively detecting NAbs against SARS‐CoV‐2, allowing to explore the relationship between the level of NAbs and the severity of the disease, and may predict the possibility of re‐infection in COVID‐19 patients. They can also be used to test the effects of monoclonal antibodies, convalescent plasma and vaccines. At present, wild‐type virus neutralization assay remains the gold standard for measuring Nabs, while pseudovirus neutralization assays, Surrogate virus neutralization test (sVNT) and high‐throughput versions of neutralization assays are popular alternatives with their own advantages and disadvantages. In this review article, we summarize the characteristics and recent progress of SARS‐CoV‐2 neutralization assays. Special attention is given to the current limitations of various neutralization assays so as to promote new possible strategies with NAbs by which rapid SARS‐CoV‐2 serological diagnosis and antiviral screening in the future will be achieved." @default.
- W3172785218 created "2021-06-22" @default.
- W3172785218 creator A5015273050 @default.
- W3172785218 creator A5026882044 @default.
- W3172785218 creator A5059637394 @default.
- W3172785218 creator A5069531935 @default.
- W3172785218 creator A5086003163 @default.
- W3172785218 creator A5089852073 @default.
- W3172785218 date "2021-06-16" @default.
- W3172785218 modified "2023-10-14" @default.
- W3172785218 title "Advances in Neutralization Assays for SARS‐CoV‐2" @default.
- W3172785218 cites W1963838989 @default.
- W3172785218 cites W2013308585 @default.
- W3172785218 cites W2112011162 @default.
- W3172785218 cites W2113925456 @default.
- W3172785218 cites W2130276289 @default.
- W3172785218 cites W2168941586 @default.
- W3172785218 cites W2376309928 @default.
- W3172785218 cites W2560458113 @default.
- W3172785218 cites W2612433850 @default.
- W3172785218 cites W2772039551 @default.
- W3172785218 cites W2903899730 @default.
- W3172785218 cites W2917605556 @default.
- W3172785218 cites W2969525890 @default.
- W3172785218 cites W2999364275 @default.
- W3172785218 cites W3007643904 @default.
- W3172785218 cites W3009335299 @default.
- W3172785218 cites W3009584253 @default.
- W3172785218 cites W3009912996 @default.
- W3172785218 cites W3010780802 @default.
- W3172785218 cites W3011537081 @default.
- W3172785218 cites W3012650581 @default.
- W3172785218 cites W3012764845 @default.
- W3172785218 cites W3013093478 @default.
- W3172785218 cites W3013742505 @default.
- W3172785218 cites W3013800395 @default.
- W3172785218 cites W3013855790 @default.
- W3172785218 cites W3014721277 @default.
- W3172785218 cites W3014735311 @default.
- W3172785218 cites W3014853902 @default.
- W3172785218 cites W3015403775 @default.
- W3172785218 cites W3017962953 @default.
- W3172785218 cites W3021544284 @default.
- W3172785218 cites W3022376279 @default.
- W3172785218 cites W3023698680 @default.
- W3172785218 cites W3024602798 @default.
- W3172785218 cites W3025232310 @default.
- W3172785218 cites W3025744748 @default.
- W3172785218 cites W3025987322 @default.
- W3172785218 cites W3027138240 @default.
- W3172785218 cites W3027910545 @default.
- W3172785218 cites W3029682964 @default.
- W3172785218 cites W3030146162 @default.
- W3172785218 cites W3032255042 @default.
- W3172785218 cites W3032394272 @default.
- W3172785218 cites W3033022675 @default.
- W3172785218 cites W3033861170 @default.
- W3172785218 cites W3035538694 @default.
- W3172785218 cites W3035950190 @default.
- W3172785218 cites W3036386821 @default.
- W3172785218 cites W3036529319 @default.
- W3172785218 cites W3036931136 @default.
- W3172785218 cites W3037085972 @default.
- W3172785218 cites W3038435002 @default.
- W3172785218 cites W3039066506 @default.
- W3172785218 cites W3039409489 @default.
- W3172785218 cites W3040004795 @default.
- W3172785218 cites W3040017923 @default.
- W3172785218 cites W3041502662 @default.
- W3172785218 cites W3041564586 @default.
- W3172785218 cites W3042323010 @default.
- W3172785218 cites W3042872631 @default.
- W3172785218 cites W3043033641 @default.
- W3172785218 cites W3044482768 @default.
- W3172785218 cites W3044660350 @default.
- W3172785218 cites W3044702419 @default.
- W3172785218 cites W3045578670 @default.
- W3172785218 cites W3045648994 @default.
- W3172785218 cites W3046309975 @default.
- W3172785218 cites W3046548218 @default.
- W3172785218 cites W3047091198 @default.
- W3172785218 cites W3047896956 @default.
- W3172785218 cites W3048799641 @default.
- W3172785218 cites W3080470999 @default.
- W3172785218 cites W3081329931 @default.
- W3172785218 cites W3082162733 @default.
- W3172785218 cites W3082734312 @default.
- W3172785218 cites W3083217488 @default.
- W3172785218 cites W3083672343 @default.
- W3172785218 cites W3083783626 @default.
- W3172785218 cites W3084083094 @default.
- W3172785218 cites W3084156220 @default.
- W3172785218 cites W3084541934 @default.
- W3172785218 cites W3084662547 @default.
- W3172785218 cites W3084666277 @default.
- W3172785218 cites W3085504216 @default.
- W3172785218 cites W3085508151 @default.
- W3172785218 cites W3085665862 @default.
- W3172785218 cites W3086192834 @default.
- W3172785218 cites W3087153161 @default.